Astrazeneca Plc
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq, Nexium, and other medicines. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the Americas, rest of Europe, Asia, Africa, and Australasia. It has a strategic agreement with Tempus and Pathos to develop the largest multimodal foundation model in oncology; CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications; and Nucs AI Inc. to develop AI-driven Response Prediction for Therapeutic Radioconjugates. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Últimos 165 días · 12/11/25 — 28/07/26
+7.11%
Precio de cierre en pesos argentinos. Fuente: data912.
Precio
$ 68.950
Var. %
0%
Precio AZN
US$ 172,48
Teórico (precio / ratio)
AZN ÷ 4
US$ 43,12
Cotización
US$ 45,07
vs teórico
+4,52%
Cotización MEP implícita
$ 1.529,84
Cotización
US$ 42,40
vs teórico
-1,67%
Cotización Cable implícita
$ 1.626,18
Sí, existe el CEDEAR de AZN (Astrazeneca Plc) en la Bolsa de Comercio de Buenos Aires (BYMA). Su ticker local es AZN.
El ticker del CEDEAR de Astrazeneca Plc en Argentina es AZN. La acción subyacente cotiza en NYSE con el símbolo AZN.
El CEDEAR AZN tiene un ratio de 4:1. Eso significa que 4 CEDEARs equivalen a 1 acción de AZN.
El CEDEAR AZN cotiza hoy a $ 68.950 en pesos argentinos, con una variación diaria de 0%.
La acción subyacente AZN (Astrazeneca Plc) cotiza a US$ 172,48 en su mercado de origen (NYSE).
El precio teórico del CEDEAR AZN se calcula dividiendo el precio de AZN por el ratio (4). Hoy resulta en US$ 43,12.
En BYMA podés operar AZN en pesos, AZND en dólar MEP y AZNC en dólar cable. Cada modalidad refleja un tipo de cambio distinto.
En esta página encontrás un gráfico con el precio histórico del CEDEAR AZN en pesos argentinos, con datos de data912.
SeekingAlpha · 29 de jul de 2026
The Oakmark Global All Cap Strategy returned 8.05% in Q2 2026, trailing its benchmark due to headwinds in software and media. Read the full analysis for more.
Benzinga · 28 de jul de 2026
U.S. stocks mixed as Dow gains 250 points amid decline in oil prices. CNN Money Fear and Greed Index shows market sentiment in Fear zone.
SeekingAlpha · 27 de jul de 2026
AstraZeneca PLC (AZN) Q2 2026 Earnings Call July 27, 2026 6:45 AM EDTCompany ParticipantsJoris Silon - Head of Investor RelationsPascal Soriot - CEO &...
SeekingAlpha · 27 de jul de 2026
AstraZeneca delivered solid core EPS growth of 18% YoY, while revenue growth came in line with expectations for the full year 2026. Read more on AZN stock here.
Benzinga · 27 de jul de 2026
Dow Jones up 0.80% to 52,361.92, NASDAQ up 0.23% to 25,024.65, S&P 500 up 0.28% to 7,432.59. Communication services up 2.5%, energy down 1.84%.
Benzinga · 27 de jul de 2026
AstraZeneca (AZN) Q2 2026: EPS beats estimates at $2.63 despite missing revenue targets. Oncology sales up 16%. Get the full recap.
Benzinga · 27 de jul de 2026
Results in 2nd and later-line Claudin 18.2-positive advanced gastric cancers versus investigator’s choice of therapy. The trial included patients with locally a…
SeekingAlpha · 27 de jul de 2026
2026-07-27. The following slide deck was published by AstraZeneca PLC in conjunction with their 2026 Q2 earnings call.
Noticias vía Finnhub